Associated Papers
Alternative splicing generates isoform diversity in MEN1.
Ramachandran A et al.
Endocrine Oncology (bristol, England), 2024
39649118 (PubMed )
Supplement: supplementary_table_3.xlsx › Supplementary_Table_3
Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.
Dreijerink KMA et al.
Epigenetics & Chromatin, 2022
35941657 (PubMed )
Supplement: 13072_2022_461_MOESM5_ESM.xlsx › Database_van_mutaties
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › ClinVar
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
Vergès B et al.
The Journal of Clinical Endocrinology and Metabolism, 2002
Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1.
Guo SS et al.
Molecular Endocrinology (baltimore, Md.), 2001
The MEN1 gene and associated diseases: an update.
Tsukada T et al.
Endocrine Pathology, 2001
Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors.
Uchino S et al.
Cancer Research, 2000
Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects.
Mutch MG et al.
Human Mutation, 1999
Select a paper to view details